Rigel Pharmaceuticals, Inc. (RIGL) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Rigel Pharmaceuticals generates stable income based on sales of Tavalisse and Rezlidhia, creating a high-quality cash flow. The EV/EBITDA valuation trend visualizes this financial foundation, where the metric value stands at 9.15. Management is successfully developing small molecules for oncology, while a balanced approach to R&D and commercialization strengthens investor confidence in the hematology portfolio.
rigel.com - analytical breakdowns and key metrics (RIGL)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Rigel Pharmaceuticals|RIGL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Rigel Pharmaceuticals, Inc.|RIGL - Company Cumulative Debt|Debt to Book Capitalization Ratio Rigel Corp|RIGL - Company Long-Term Loans and Borrowings|Company Short-Term Debts Rigel Pharmaceuticals|Quick Ratio rigel.com
- business earnings and investment ratios data:
RIGL - Annual Net Income|Projected Future Earnings Rigel Pharmaceuticals|RIGL - Market Cap to Earnings|Future Price to Earnings Rigel Pharmaceuticals|RIGL - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Rigel Corp|RIGL - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Rigel Pharmaceuticals|RIGL - Earnings per one share for the last 12 months|Quarterly EPS earnings growth rigel.com|RIGL - Earnings per share increase in current year|Earnings growth forecast for next year Rigel Pharmaceuticals
Initial company analysis:RIGL (Rigel Pharmaceuticals Inc)
High margins for Rigel Pharmaceuticals (RIGL) within the hematology niche enable the company to efficiently service its obligations, as clearly reflected by the EV/EBITDA ratio accounting for financial leverage. This indicator compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, allowing investors to assess the real value of assets without tax distortions and determine the risk of overpaying for leveraged capital.
Key competitors
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation DNTH (Dianthus Corp)|PHVS: EV/EBITDA Multiple|ABCL - Total Company Value to Operating Income Before Depreciation Ratio|TRML (Tourmaline Bio) - EV/EBITDA Multiple|PGEN - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple PHAR|NKTR - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|zenasbio.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMNM: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GOSS (Gossamer Bio Inc)|KalVista Pharmaceuticals Inc (KALV) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SEPN (Septerna Pharma)|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|SVRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANAB|EV/EBITDA Multiple Astria Therapeutics Inc (ATXS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization enGene Bio ENGN|Business Value to Operating Income Before Depreciation RAPT|JBIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|aclaristx.com (ACRS) - Enterprise Value to EBITDA Ratio|KYTX: EV/EBITDA Multiple|Tiziana Life Sciences Ltd. (TLSA) - EV/EBITDA Multiple|CABA (Cabaletta Bio, Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Ventyx Biosciences, Inc (VTYX)|EV/EBITDA Multiple THTX|AVTX - Company Value to EBITDA|Eledon Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Agenus, Inc. AGEN|CLYM: Enterprise Value to EBITDA Ratio|zurabio.com - Enterprise Value to Operating Income Before Depreciation Ratio|ATYR: EV/EBITDA Multiple|ADAG - Total Company Value to Operating Income Before Depreciation Ratio|IMA (ImageneBio) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Shattuck Therapeutics (STTK)|EV/EBITDA Multiple EQ|EV/EBITDA Multiple connectbiopharm.com (CNTB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic IMUX|Atara Biotherapeutics, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IFRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio X4 Pharmaceuticals Inc. XFOR|adicetbio.com (ACET) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Celularity - Business Value to Operating Income Before Depreciation|INMB (INmune Bio, Inc.) - EV/EBITDA Multiple|barinthusbio.com (BRNS) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple KZR|SAB Biotherapeutics Inc. (SABS) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|Enlivex Therapeutics Ltd - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QTTB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GOVX|EDSA: EV/EBITDA Multiple|iBio Inc - Business Value to Operating Income Before Depreciation|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple XTL Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics (BOLT)|HCWB (hcwbiologics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|AIM - Enterprise Value to EBITDA Ratio|Aditxt Corp - EV/EBITDA Multiple|GRI - EV/EBITDA Multiple|XRTX (XORTX Therapeutics Inc.) - Enterprise Value to EBITDA Ratio|reshapelifesciences.com - Business Value to Operating Income Before Depreciation|REVB (Revelation Biosciences, Inc.) - EV/EBITDA Multiple|Indaptus Therapeutics Inc (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|Enterprise Value to EBITDA Ratio calcimedica.com CALI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK: Enterprise Value to EBITDA Ratio|IGMS - EV/EBITDA Multiple|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OCEA|TCBP (TC Biopharm) - EV/EBITDA Multiple|Company Value to EBITDA thirdharmonicbio.com THRD
